Efficacy and safety of bevacizumab in Turkish patients with metastatic and recurrent cervical cancer
Rattachement africain : tr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE: To evaluate the efficacy of bevacizumab a monoclonal, antivascular endothelial growth factor antibody in combination with cytotoxic chemotherapy in Turkish patients with recurrent and metastatic cervical cancer. MATERIALS AND METHODS: Data of 64 patients with metastatic or recurrent cervical cancer, receiving bevacizumab with first-line cisplatin or carboplatin and paclitaxel chemotherapy between 2013 and 2017 were retrospectively evaluated. RESULTS: The mean age of the patients was 49 years (range, 28-68), the median follow-up time was 12 months (range, 2-53), the median progression-free survival (PFS) was eight months, and the median overall survival (OS) was 23 months. All 64 patients received a median of 6 (range, 1-12) bevacizumab and 6 (range, 2-12) chemotherapy cycles. The chemotherapy regimens used with bevacizumab were cisplatin and paclitaxel in 31 (48%) and carboplatin and paclitaxel in 33 (52%) patients. The survival in patients treated with bevacizumab and cisplatin plus paclitaxel was better-particularly in patients with no previous cisplatin-based radiosensitizer therapy-than those treated with carboplatin, paclitaxel, and bevacizumab (p=0.023). The bevacizumab dose was 7.5 mg/kg in 30 patients (47%) and 15 mg/kg in 34 patients (53%) every 21 days. No significant difference was reported in the OS and the PFS between the two groups. While the most common all-grades adverse events were nausea, neutropenia, anemia, and peripheral sensory neuropathy, the most common grade ≥3 adverse events were neutropenia, anemia, and peripheral sensory neuropathy. CONCLUSION: Adding bevacizumab to platinum and paclitaxel chemotherapy in a case of metastatic or recurrent cervical cancer is an effective and tolerable treatment for Turkish patients.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Efficacy and safety of bevacizumab in Turkish patients with metastatic and recurrent cervical cancer
- Date Crossref
- 29/07/2020
- Éditeur
- Galenos Yayinevi
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi pays non établi dans la noticeÉtablissement de santé
-
Izmir University pays non établi dans la noticeUniversité ou école supérieure
-
Sağlık Bilimleri Üniversitesi pays non établi dans la noticeUniversité ou école supérieure
-
Kayseri Eğitim ve Araştırma Hastanesi pays non établi dans la noticeÉtablissement de santé
-
Istanbul Medeniyet University pays non établi dans la noticeUniversité ou école supérieure
-
Kartal Dr. Lütfi Kırdar Training and Research Hospital pays non établi dans la noticeÉtablissement de santé
-
University of Health Sciences Turkey pays non établi dans la noticeUniversité ou école supérieure
-
Kayseri Training and Research Hospital pays non établi dans la noticeÉtablissement de santé
-
Göztepe Training and Research Hospital İstanbul Medeniyet Universtiy pays non établi dans la noticeÉtablissement de santé
Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi, Izmir University et Sağlık Bilimleri Üniversitesi, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.